Advances in deciphering the pathogenesis of ITP have facilitated the development of a number of new targeted therapies, such as those based on the inhibition of Syk inhibitors, Bruton’s tyrosine kinase (BTK), neonatal Fc receptors, or the complement pathway. This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.